**Dunlevie MFM Center Spring 2024 Fetal Therapy Virtual Symposium**

**May 2, 2024**

|  |  |  |
| --- | --- | --- |
| **Time** | **Name** | **Presentation title** |
| **5:00 – 5:10pm** | Yair Blumenfeld, MD | Welcome and introductions |
| **5:10 – 5:30pm** | Dena Matalon, MD | Diagnostic advances and challenges of carrier screening |
| **5:30 – 5:35pm** | Q&A |  |
| **5:35 – 5:55pm** | Agnieszka Czechowicz, MD, PhD | In utero hemopoietic stem cell transplantation for Fanconi anemia |
| **5:55 – 6:00pm** | Q&A |  |
| **6:00 – 6:20pm** | Alireza Shamshirsaz, MDBoston Children’s Hospital, Harvard Medical School | Mammalian target of rapamycin (mTOR) inhibitors: A new-possible approach for in-utero medication therapy |
| **6:20 – 6:25pm** | Q&A |  |
| **6:25 – 6:30pm** | **Break** |  |
| **6:30 – 6:50pm** | Carlos Milla, MD | Highly-effective CFTR modulator therapy as an early intervention to avert organ damage in CF |
| **6:50 – 6:55pm** | Q&A |  |
| **6:55 – 7:15pm** | Michelle Kaplinski, MD | Fetal arrhythmias – updates and innovations |
| **7:15 – 7:20pm** | Q&A |  |
| **7:20 – 7:40pm** | Natali Aziz, MD, MS | Congenital CMV: Is it time to reconsider our screening and management strategies? |
| **7:40 – 7:45pm** | Q&A |  |
| **7:45 – 8:00pm** | Symposium conclusion |  |